ReviewAnnals of medicine2025

Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy.

Milan Jovanovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.